Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 16/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 15/20 | 0.56 |
| ▸ | AGT | P01019 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9387490 | 0.86 | AGTR1 (0.59) | AGTR1AGTR2AGT | |
| SCHEMBL9385591 | 0.86 | AGTR1 (0.61) | AGTR1AGTR2AGT | |
| SCHEMBL9068740 | 0.85 | AGTR1 (0.55) | AGTR1AGTR2AGT | |
| SCHEMBL243845 | 0.85 | AGTR1 (0.62) | AGTR1AGTR2 | |
| SCHEMBL9276766 | 0.85 | AGTR1 (0.57) | AGTR1AGTR2AGT | |
| SCHEMBL14855449 | 0.84 | AGTR1 (0.62) | AGTR1AGTR2AGT | |
| SCHEMBL9276943 | 0.84 | AGTR1 (0.57) | AGTR1AGTR2AGT | |
| SCHEMBL7303260 | 0.83 | AGTR1 (0.61) | AGTR1AGTR2AGT | |
| SCHEMBL7400468 | 0.83 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL9277433 | 0.82 | AGTR1 (0.55) | AGTR1AGTR2AGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5545651-A | HYPOTENSIVE AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| US-5395844-A | Hypotensive agents; congestive heart failure | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| WO-1994028896-A1 | IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-12-22 | — | — | WO | disclosed |